

Suda Pharmaceuticals Limited

ACN 090 987 250

SUPPLEMENTARY PROSPECTUS

Important Information

This is a supplementary prospectus (**Supplementary Prospectus**) intended to be read with the prospectus dated 29 June 2018 (**Prospectus**) issued by Suda Pharmaceuticals Limited (**Company**).

This Supplementary Prospectus is dated 31 July 2018 and was lodged with the Australian Securities and Investments Commission (**ASIC**) on that day. Neither ASIC nor ASX (and their respective officers) take any responsibility as to the contents of this Supplementary Prospectus.

To the extent of any inconsistency between this Supplementary Prospectus and the Prospectus, this Supplementary Prospectus will prevail. Unless otherwise indicated, terms defined and used in the Prospectus have the same meaning in this Supplementary Prospectus.

This is an important document and should be read in its entirety. If you do not understand it you should consult your professional advisors without delay.

1 INCREASE IN NUMBER OF SECURITIES OFFERED

The Company increases the number of New Shares offered under the Shortfall Offer by 133,675,200, together with one free attaching Listed Option for every two New Shares issued.

2 LISTED OPTION EXPIRY DATE

The expiry date of a Listed Option is 30 June 2020.

3 DIRECTORS' AUTHORISATION

This Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors.

In accordance with section 720 of the Corporations Act, each Director has consented to the lodgement of this Supplementary Prospectus with ASIC.

Dated: 31 July 2018

A handwritten signature in black ink, appearing to read 'Joseph Ohayon', with a long horizontal flourish extending to the right.

Joseph Ohayon

CFO/Company Secretary

On behalf of Suda Pharmaceuticals Limited